COMP <GO>
CELU vs ABVC // EV/EBITDA & P/E VALUATION
Celularity Inc. (Class A) (NASDAQ) VS. ABVC BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: CELU 0
— ABVC 2
■ METRIC PARITY
LAST: $0.85 (-9.66%) • MKT CAP: $27.6M
valuation
—
LAST: $1.04 (-4.59%) • MKT CAP: $27.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CELU VS. ABVC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CELU | ABVC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 24.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.76% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -51.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 1/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.9 | 48.3 | -12.33 | ABVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.6M | $27.8M | -$201.9K | ABVC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CELU REV | ABVC REV | CELU GROSS % | ABVC GROSS % | CELU FCF | ABVC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $26.6M | $0 | 24.4% | — | -$13.3M | -$3.0M |
| FY 2024 | $54.2M | $509.6K | 72.4% | 98.0% | -$6.6M | -$1.8M |
| FY 2023 | $22.8M | $152.4K | — | — | -$38.7M | -$4.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CELU // BETA —
ABVC // BETA —